Interpretation of results of the cost-effectiveness analysis reported by Pellissier et al. on October 2007.
Najafzadeh
M
M
Sadatsafavi
M
M
Marra
C A
CA
D003362:Cost-Benefit Analysis; D006562:Herpes Zoster / Q000517:prevention & control*; D053061:Herpes Zoster Vaccine / Q000191:economics*; D006801:Humans; D032541:Mass Vaccination / Q000191:economics; D008875:Middle Aged
D053061:Herpes Zoster Vaccine